No clinically significant dissimilarities within the pharmacokinetics of midazolam (CYP3A4 substrate) or its metabolite one-hydroxymidazolam were noticed when utilised concomitantly with one or a number of doses of lumateperone in patients with schizophrenia.The site is protected. The https:// assures that you will be connecting to your Formal Web-